Partnering with owners and management, ArchiMed and the CDPQ invest in Corealis Pharma

The significant recapitalization of the Americas' leading CDMO for pharmaceutical oral solid dosage formulation and clinical supply manufacturing will accelerate growth, including the build-out of State-of-the-Art Laboratories and Good Manufacturing Practices-compliant facilities.

LYON, France and MONTRÉAL and LAVAL, QC, May 31, 2022 /CNW Telbec/ - Trans-Atlantic private equity healthcare specialist ArchiMed and global investor group Caisse de dépôt et placement du Québec (CDPQ) have invested in Corealis Pharma. The partnership will further expand the high-quality drug development services Corealis offers as a Contract Development and Manufacturing Organization to small and medium-sized biotech and pharma companies.

Founded in 2005 and based in Laval, Québec, Canada, Corealis is the market-leading CDMO in the Americas for the formulation development and manufacture of oral solid dosage pharmaceuticals – tablets, capsules, and granules – during pre-commercialization preclinical and clinical phases.

NewsGuest UserJune 7, 2022ArchiMed, Corealis, clinical supply manufacturing